Apolipoprotein B is a new target of the GDNF/RET and ET-3/EDNRB signalling pathways
Version of Record online: 16 AUG 2012
© 2012 Blackwell Publishing Ltd
Neurogastroenterology & Motility
Volume 24, Issue 10, pages e497–e508, October 2012
How to Cite
Evangelisti, C., Bianco, F., Pradella, L. M., Puliti, A., Goldoni, A., Sbrana, I., Rossi, M., Vargiolu, M., Seri, M., Romeo, G., Stanghellini, V., de Giorgio, R. and Bonora, E. (2012), Apolipoprotein B is a new target of the GDNF/RET and ET-3/EDNRB signalling pathways. Neurogastroenterology & Motility, 24: e497–e508. doi: 10.1111/j.1365-2982.2012.01998.x
- Issue online: 12 SEP 2012
- Version of Record online: 16 AUG 2012
- Received: 20 January 2012 Accepted for publication: 9 July 2012
Figure S1. Cell morphology classification. Cells were classified according to the presence and shape of neurites as follows: undifferentiated, round-shaped cells (A); with one neurite (monopolar) (B), with two opposite neurites (bipolar) (C); with two opposite and branched neurites (branched-bipolar) (D), with many neurites (star cells) (E); with one prevalent branched neurite (branched) (F).
Figure S2. (A) Western blot analysis of GDNF-treated Neuro2a in absence or presence (last 4 lanes) of Triciribine V, an Akt inhibitor. (B) qRT-PCR for Apob expression in GDNF-treated Neuro2a in presence of Triciribine V. (C) Western blot analysis of GDNF-treated Neuro2a in absence or presence (last 4 lanes) of PD98059, a specific ERK inhibitor. (F) qRT-PCR for Apob expression in GDNF-treated Neuro2a in presence of PD98059.
Figure S3. Luciferase activity assay for the different constructs, compared to the predicted promoter (900 bp construct), in absence of GDNF stimulation.
|NMO_1998_sm_FigS1-3.docx||322K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.